Plus Therapeutics Announces Reverse Stock Split

The 1-for-25 reverse stock split aims to increase the per share trading price to comply with Nasdaq's minimum bid price requirement.

Mar. 31, 2026 at 12:33pm

Got story updates? Submit your updates here. ›

A highly detailed, black-and-white close-up photograph of the inner workings of a complex banking machine, capturing the industrial strength and precision of financial infrastructure.An extreme close-up of the intricate machinery powering the financial markets reflects the technical complexities behind a reverse stock split.Houston Today

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, announced that its Board of Directors has approved a 1-for-25 reverse stock split of its common stock. The reverse split will become effective on April 2, 2026, reducing the company's outstanding shares from approximately 171.6 million to 6.9 million. The move is intended to increase the per share trading price to meet Nasdaq's minimum $1.00 bid price requirement for continued listing.

Why it matters

Reverse stock splits are a common tactic used by publicly traded companies to boost their share price and avoid delisting from major exchanges like Nasdaq. By reducing the number of outstanding shares, the price per share increases, potentially helping Plus Therapeutics regain compliance with Nasdaq's listing rules.

The details

The reverse stock split will combine every 25 shares of Plus Therapeutics' common stock into 1 share, with no change to the $0.001 par value per share. No fractional shares will be issued, and stockholders will instead receive a cash payment for any fractional shares. The company's transfer agent, Broadridge Financial Services, will handle the exchange process for stockholders.

  • The reverse stock split will become effective at 12:01 a.m. Eastern Time on April 2, 2026.
  • Plus Therapeutics' common stock will begin trading on a post-split basis on The Nasdaq Capital Market on April 2, 2026 under the existing trading symbol 'PSTV'.

The players

Plus Therapeutics, Inc.

A clinical-stage pharmaceutical company developing targeted radiotherapeutics for central nervous system cancers.

Broadridge Financial Services, Inc.

The transfer agent retained by Plus Therapeutics to handle the exchange process for the reverse stock split.

Got photos? Submit your photos here. ›

What’s next

The reverse stock split is expected to help Plus Therapeutics regain compliance with Nasdaq's minimum $1.00 bid price requirement for continued listing on the exchange.

The takeaway

Reverse stock splits are a common tactic used by publicly traded companies to boost their share price and avoid delisting from major exchanges. Plus Therapeutics is implementing this 1-for-25 reverse split in an effort to meet Nasdaq's listing standards and maintain its public trading status.